A 'fit' microbiota to potentiate cancer immunotherapy

about

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment Do checkpoint inhibitors rely on gut microbiota to fight cancer?The microbiota revolution: Excitement and caution.

P2860

Q28076294-8589EF7F-4C73-47BE-9A1E-C888D6A1D50B Q39380597-D349D90D-26C7-4A9C-8B24-906A7E413F7A Q39413324-FC02804A-2AF9-4C03-959E-9854376A4DB7

P2860

A 'fit' microbiota to potentiate cancer immunotherapy

Item

http://www.wikidata.org/entity/Q35874071

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A 'fit' microbiota to potentiate cancer immunotherapy

@ast

A 'fit' microbiota to potentiate cancer immunotherapy

@en

type

Item

label

A 'fit' microbiota to potentiate cancer immunotherapy

@ast

A 'fit' microbiota to potentiate cancer immunotherapy

@en

prefLabel

A 'fit' microbiota to potentiate cancer immunotherapy

@ast

A 'fit' microbiota to potentiate cancer immunotherapy

@en

P1476

A 'fit' microbiota to potentiate cancer immunotherapy

@en

P2093

Maria Rescigno

http://www.w3.org/2001/XMLSchema#string

P2860

A human gut microbial gene catalogue established by metagenomic sequencing

Interactions between the microbiota and the immune system

Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life.

BALB/c and C57BL/6 Mice Differ in Polyreactive IgA Abundance, which Impacts the Generation of Antigen-Specific IgA and Microbiota Diversity.

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

P2888

s13073-015-0256-x

P304

131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13073-015-0256-X

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maria Rescigno

P577

2015-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287805258

http://www.w3.org/2001/XMLSchema#string

P6179

1052181608

http://www.w3.org/2001/XMLSchema#string

P698

26689196

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

4687315

http://www.w3.org/2001/XMLSchema#string

A 'fit' microbiota to potentiate cancer immunotherapy

about

P2860

P2860

A 'fit' microbiota to potentiate cancer immunotherapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P921

P932